Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea.
Department of Translational Medicine, University Piemonte Orientale, Novara, Italy.
ESMO Open. 2023 Jun;8(3):101541. doi: 10.1016/j.esmoop.2023.101541. Epub 2023 May 11.
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer (MBC) was published in 2021. A special, hybrid guidelines meeting was convened by ESMO and the Korean Society of Medical Oncology (KSMO) in collaboration with nine other Asian national oncology societies in May 2022 in order to adapt the ESMO 2021 guidelines to take into account the differences associated with the treatment of MBC in Asia. These guidelines represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with MBC representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). The voting was based on the best available scientific evidence and was independent of drug access or practice restrictions in the different Asian countries. The latter were discussed when appropriate. The aim of these guidelines is to provide guidance for the harmonisation of the management of patients with MBC across the different regions of Asia, drawing from data provided by global and Asian trials whilst at the same time integrating the differences in genetics, demographics and scientific evidence, together with restricted access to certain therapeutic strategies.
欧洲肿瘤内科学会（ESMO）最新版的转移性乳腺癌（MBC）诊断、分期和治疗临床实践指南于 2021 年发布。为了使 ESMO 2021 指南适应亚洲 MBC 治疗相关的差异，ESMO 与韩国肿瘤学会（KSMO）合作，于 2022 年 5 月召集了一次特殊的、混合的指南会议，该会议由 ESMO 和九个其他亚洲国家肿瘤学会共同召开。这些指南代表了来自亚洲 MBC 治疗领域的专家组的共识意见，这些专家代表了中国临床肿瘤学会（CSCO）、印度肿瘤学会（ISMPO）、印度尼西亚肿瘤学会（ISHMO）、日本肿瘤学会（JSMO）、韩国肿瘤学会（KSMO）、马来西亚肿瘤学会（MOS）、菲律宾肿瘤学会（PSMO）、新加坡肿瘤学会（SSO）、中国台湾肿瘤学会（TOS）和泰国肿瘤学会（TSCO）的肿瘤学会。投票是基于最佳可用的科学证据进行的，独立于亚洲不同国家的药物准入或实践限制。在适当的时候会讨论这些限制。这些指南的目的是为亚洲不同地区的 MBC 患者管理提供指导，借鉴全球和亚洲试验提供的数据，同时整合遗传、人口统计学和科学证据方面的差异，以及对某些治疗策略的限制准入。
